Enter multiple symbols separated by commas

Stocks Celgene Corp


  • NEW YORK/ ATLANTA, Oct 5- The Pacific trade deal agreed on Monday, which grants biotechnology drug producers less protection than offered by the United States, could put more downward pressures on the costly drugs' pricing in the industry's most lucrative market. The United States and 11 trading partners, including Mexico, Japan, Canada and Australia, wrapped up...

  • US STOCKS-Futures rise as investors await host of data Thursday, 1 Oct 2015 | 7:24 AM ET

    Oct 1- U.S. stock index futures started the last quarter of the year on a positive note on Thursday as weak data from China raised hopes of more stimulus measures from Beijing and investors awaited a slew of U.S. data. *Data showed factory activity in China shrank again in September, leading some investors to believe that the government will be more aggressive in its...

  • Patent and Trademark Office on Friday denied a request by Celgene Corp to sanction Bass and his Coalition for Affordable Drugs by throwing out their challenges to its patents. Celgene in July accused Bass of abusing the patent review process by short-selling pharmaceutical shares that drop when a patent review is filed. A spokeswoman for Bass' $2 billion...

  • Lightning Round: It's a winner, don't back away Friday, 25 Sep 2015 | 7:13 PM ET
    Mad Money Lightning Round

    Jim Cramer gives his opinion on caller favorite stocks, including this stock that was recently taken to the woodshed.

  • What a week for biotechs: Drop into bear territory Friday, 25 Sep 2015 | 3:33 PM ET

    Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.

  • NEW YORK, Sept 25- The S&P 500 and Nasdaq turned lower in afternoon trading, dragged down by a drop in biotech shares. The Nasdaq Biotech Index was down 6.2 percent, led lower by a 5.6 percent drop in Celgene. Democratic presidential candidate Hillary Clinton said she would announce a plan to stop "price gouging" for specialty drugs, sparking a fall in the shares.

  • Sept 23- Drug developer OncoGenex Pharmaceuticals Inc said its experimental combination therapy for pancreatic cancer was not effective in a mid-stage study. The intravenous drug, apatorsen, when added to Celgene Corp's combination treatment of Abraxane and chemotherapy drug gemcitabine, did not show any survival benefit when compared with the Abraxane...

  • These outperforming stocks are looking risky Wednesday, 16 Sep 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City.

    Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.

  • Power Play: Making money in biotech Tuesday, 8 Sep 2015 | 1:21 PM ET
    Employees at Biogen Idec in Cambridge, MA

    What to buy in biotech

  • Why we moved to 100% cash: CIO Friday, 4 Sep 2015 | 3:39 PM ET
    Cash dollars

    Here's why one market expert is sitting on the sidelines right now, and when he thinks it's a good time to get back in.

  • Aug 31- Wall Street ended lower on Monday and wrapped up its worst month since 2012 after a senior Federal Reserve official heightened fears among investors of a potential U.S. interest hike in September. Fed Vice Chairman Stanley Fischer on Saturday said U.S. inflation would likely rebound as pressure from the dollar fades, allowing the Fed to raise interest...

  • Cramer Remix: Surprise! This group has a pulse Thursday, 27 Aug 2015 | 7:17 PM ET
    Jim Cramer on Mad Money.

    It may be down, but today’s action has “Mad Money” host Jim Cramer questioning whether this sector is really out.

  • Cramer: China could cause your biotech to nosedive Thursday, 27 Aug 2015 | 6:25 PM ET

    Jim Cramer explains that those big pharma and biotech stocks that seem like a safe-haven could be impacted by the troubles in China.

  • Health care remains the best bet: Strategist Wednesday, 26 Aug 2015 | 2:26 PM ET
    Traders work on the floor of the New York Stock Exchange.

    The healthcare secular theme isn't new, but is still very much in force.

  • Celgene Corp has alleged Bass is abusing a process set up to challenge patents by short selling pharmaceutical shares that drop when a patent review is filed. Last month, Celgene, one of the world's largest biotechnology firms, asked the patent office to sanction Bass and others behind the coalition by throwing out its patent challenges. Celgene said Bass' real...

  • Safe harbor for investors as markets dive: Analysts Tuesday, 11 Aug 2015 | 4:46 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Investors are bracing for a bumpy ride after China devalued the yuan by nearly 2 percent. Here are some possible safe stock bets.

  • UK's AstraZeneca beats profit forecasts Thursday, 30 Jul 2015 | 3:05 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter.

  • LONDON, July 30- AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar. Chief Executive Pascal Soriot, who fended off a $118 billion takeover attempt by Pfizer last year, is banking on a promising pipeline of new drugs-...

  • NEW YORK, July 29- Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its...

  • *Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...